CHMP positive on Orexigen's obesity product
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion to Orexigen Therapeutics' naltrexone HCI / bupropion HCI prolonged release formulation as Mysimba for use in treating obesity.